Tuberculosis Collection

The Implementation of Rifapentine and Isoniazid (3HP) in Two Remote Arctic Communities with a Predominantly Inuit Population, the Taima TB 3HP Study

2020

Alvarez, G.G., Van Dyk, D., Mallick, R., Lesperance, S., Demaio, P., Finn, S., Edmunds Potvin, S., Patterson, M., Pease, C., Amaratunga, K., Hui, C., Cameron, D.W., Mulpuru, S., Aaron, S.D., Momoli, F., & Zwerling, A.

Taylor & Francis

Description

The authors present findings from a prospective two-year observational study involving the introduction of a shorter regimen of latent TB infection treatment with rifapentine and isoniazid once weekly for 12 weeks (3HP) among Inuit patients in two Nunavut communities. The authors assessed treatment completion rates between the 3HP group and an historical control group and examined the safety of 3HP treatment and the factors associated with 3HP completion.

Link to Resource

The Implementation of Rifapentine and Isoniazid (3HP) in Two Remote Arctic Communities with a Predominantly Inuit Population, the Taima TB 3HP Study.

Alvarez, G.G., Van Dyk, D., Mallick, R., Lesperance, S., Demaio, P., Finn, S., Edmunds Potvin, S., Patterson, M., Pease, C., Amaratunga, K., Hui, C., Cameron, D.W., Mulpuru, S., Aaron, S.D., Momoli, F., & Zwerling, A. (2020). The implementation of rifapentine and isoniazid (3HP) in two remote Arctic communities with a predominantly Inuit population, the Taima TB 3HP study. International Journal of Circumpolar Health, 79(1), 1758501.

Publication Form

Comments
Please Copy the Captcha Protection Text